Skye Bioscience, Inc. (SKYE)
2.03
-0.14
(-6.45%)
USD |
NASDAQ |
Aug 25, 16:00
2.03
0.00 (0.00%)
After-Hours: 16:53
Skye Bioscience Total Liabilities (Quarterly) : 11.53M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.53M |
| March 31, 2026 | 10.40M |
| December 31, 2025 | 8.290M |
| September 30, 2025 | 8.488M |
| June 30, 2025 | 8.484M |
| March 31, 2025 | 5.543M |
| December 31, 2024 | 4.612M |
| September 30, 2024 | 5.732M |
| June 30, 2024 | 14.45M |
| March 31, 2024 | 15.95M |
| December 31, 2023 | 14.07M |
| September 30, 2023 | 13.91M |
| June 30, 2023 | 10.03M |
| March 31, 2023 | 9.368M |
| December 31, 2022 | 12.12M |
| September 30, 2022 | 6.154M |
| June 30, 2022 | 5.269M |
| March 31, 2022 | 4.238M |
| December 31, 2021 | 3.991M |
| September 30, 2021 | 3.422M |
| June 30, 2021 | 3.217M |
| March 31, 2021 | 2.92M |
| December 31, 2020 | 2.221M |
| September 30, 2020 | 2.496M |
| June 30, 2020 | 3.322M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.376M |
| December 31, 2019 | 1.449M |
| September 30, 2019 | 18.13M |
| June 30, 2019 | 14.72M |
| March 31, 2019 | 32.59M |
| December 31, 2018 | 17.52M |
| September 30, 2018 | 11.32M |
| June 30, 2018 | 10.29M |
| March 31, 2018 | 8.912M |
| December 31, 2017 | 1.357M |
| September 30, 2017 | 2.448M |
| June 30, 2017 | 2.262M |
| March 31, 2017 | 1.847M |
| December 31, 2016 | 1.774M |
| September 30, 2016 | 1.711M |
| June 30, 2016 | 1.337M |
| March 31, 2016 | 3.360M |
| December 31, 2015 | 3.040M |
| September 30, 2015 | 3.515M |
| June 30, 2015 | 1.682M |
| March 31, 2015 | 0.8071M |
| December 31, 2014 | 0.8019M |
| September 30, 2014 | 0.3495M |
| April 30, 2014 | 0.0493M |
| January 31, 2014 | 0.0538M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 10.02B |
| Viking Therapeutics, Inc. | 113.58M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 11.03M |
| Shareholders Equity (Quarterly) | -0.4973M |
| Debt to Equity Ratio | -0.3593 |
| Current Ratio | 0.9504 |
| Net Debt Paydown Yield | 0.19% |